Article

CIBA Vision voluntarily recalls spherical contact lens

Duluth, GA-CIBA Vision Corp. is voluntarily recalling select lots of its spherical O2Optix (lotrafilcon B) soft contact lenses in the United States and other countries. None of the company’s other lenses is involved in the recall.

Duluth, GA-CIBA Vision Corp. is voluntarily recalling select lots of its spherical O2Optix (lotrafilcon B) soft contact lenses in the United States and other countries. None of the company’s other lenses is involved in the recall.

“We identified that some lenses in these lots may fall below our standard for ion permeability, a material characteristic that correlates with lens movement on the eye,” said William D. Schaeffer, global head of quality for CIBA Vision, in the Jan. 12 recall notice. The FDA is aware of the action, according to the company.

The recalled lenses were distributed between September and December 2006.

“The potential medical safety risk to consumers posed by lenses with reduced ion permeability includes discomfort, foreign body irritation, and superficial localized corneal staining,” Schaeffer wrote. “The possibility of occurrence of these findings is moderate. As with any staining of the corneal tissue, the risk of corneal infection is somewhat increased, although the probability is remote.”

A separate company statement indicated that symptoms typically resolve within 2 to 24 hours of lens removal. The company has improved its manufacturing processes and has addressed the ion permeability issue, the statement said. Lens availability in the United States is expected to be affected into the second quarter of the year.

For more information, a list of affected lots, and instructions on returning lenses to the company, see www.us.cibavision.com/lenses/statement.shtml.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.